Handheld Ultrasound Developer Exo Raised $220M In Series C
As Exo awaits FDA clearance for its handheld ultrasound device, it will use the new funding for planned commercialization. Exo has raised more than $320m to date.
You may also be interested in...
Since going public, the company’s share price has flopped, its board has seen a flurry of appointments and resignations over the past year, and now the company is facing investor lawsuits.
In an interview with Medtech Insight, Another newcomer to the handheld ultrasound market weighed in on the competitive environment.
The new version of Philips' Lumify gives clinicians access to pulse wave Doppler ultrasound technology, providing real-time blood flow information.